Document Detail


Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction.
MedLine Citation:
PMID:  11269739     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The highly schedule-dependent cytotoxic agent etoposide (VP-16) is initially effective in the treatment of small-cell lung cancer (SCLC), particularly in multidrug combination chemotherapy. Heterogeneity in cellular sensitivity to cell cycle arrest may underpin the inadequacy of low-dose extended-cycle single-agent regimes in tumours with partially dysfunctional apoptotic signalling pathways. We have studied the longevity and dose dependency of cell cycle and to a limited extent the apoptotic responses of a panel of seven unselected SCLC cell lines, screened for TP53 status. METHODS: Cells were analysed using flow cytometry for the cell cycle responses and field inversion gel electrophoresis for apoptotic patterns. The mitotic inhibitor nocodazole was used to assess and correct cell line response data for differences in cell cycle traverse per se. RESULTS: An overall lack of G1/S arrest and muted DNA fragmentation were consistent with the presence of TP53 gene abnormalities. Maximal G2 arrest but with clear recovery potential occurred at an exposure dose (ED, concentration of drug x time) value of approximately 24 microM h. Higher doses (ED values >48 microM h) revealed a wide variation in S phase delay that was independent of population doubling time and could not be compensated for by drug concentration changes alone. CONCLUSION: The results suggest that heterogeneity in the in vitro sensitivity of unselected SCLC cell lines to S phase arrest is demonstrable at ED values projected to be critical for clinical activity. Such variation in S phase responsiveness may reflect differences in checkpoint activation and offer a functional target for the design of more-effective combination therapy.
Authors:
S Soués; M Wiltshire; P J Smith
Related Documents :
4050789 - Endogenous blockage and delay of the chromosome cycle despite normal recruitment and gr...
1474189 - Cell cycle analysis by flow cytometry of non-exposed, sun-exposed, and tretinoin-treate...
7292249 - Relation of cell cycle position and chromatin decondensation to ectopic hormone synthes...
1650609 - Differentiation of hl-60 myeloid leukaemia cells is associated with a transient block i...
2549409 - Comparison of gamma-radiation-induced accumulation of ataxia telangiectasia and control...
15197559 - Differences in centromere positioning of cycling and postmitotic human cell types.
22997199 - Heterogeneity in histone 2b-green fluorescent protein-retaining putative small intestin...
21344189 - Hydrogen peroxide is not involved in hrpn from erwinia amylovora-induced hypersensitive...
24318339 - Changes in the composition of cotton fibre cell walls during development.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  47     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2001  
Date Detail:
Created Date:  2001-03-27     Completed Date:  2001-04-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  133-40     Citation Subset:  IM    
Affiliation:
Laboratoire de Biologie Cellulaire, UFR Biomédicale des Saints Pères, Université René Descartes--Paris V, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / pharmacology*
Carcinoma, Small Cell / drug therapy*,  pathology
DNA Fragmentation / drug effects
Etoposide / pharmacokinetics,  pharmacology*
G1 Phase
Genes, p53
Humans
Lung Neoplasms / drug therapy*,  pathology
S Phase / drug effects*
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 33419-42-0/Etoposide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP ...
Next Document:  Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition w...